requiring supplemental oxygen
[대역어] None
[용어속성] Treatment
[용어속성] Treatment
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
24 hour
Ability
absence
accompany
activity
Administered
administration
Admission
adverse events
Affect
age
alkaline phosphatase
allergy
ALT
alternative hypothesis
ambient
analysis
Analysis
ANC
Anti-inflammatory
anticipated
antipyretics
antivirals
Arm
ARMS
assumed
AST
Baltimore
baseline
benefit
blinded
block
block randomization
Blood
breastfeeding women
Bronchoalveolar lavage
calculated
Care
Cellulose
center
Chest
chest X-ray
childbearing potential
clinical
clinical condition
Clinical course
clinical impact
Clinical improvement
Clinical outcome
clinical status
clinical trial
collected
competing
Compliance
concealed
Concentration
Concomitant
conditions
conducted
congestive heart failure
Contraception
Control
control arm
Conventional
Corticosteroids
COVID-19
COVID-19 disease
COVID-19 infection
COVID-19 pandemic
criteria
criterion
Critical
CT scan
current
Day
Declaration of Helsinki
decrease
defined
detect
direct bilirubin
disease
disorder
dissemination
dose
double-blind
drug
Drug administration
drug-drug interaction
drugs
Duration
ECMO
Efficacy
Efficacy and safety
element
eligible
endosomal pH
Enrollment
ethnic group
evaluate
Evidence
exclusion
expected
exploratory endpoint
extracorporeal membrane oxygenation
Face mask
FDA
Fisher
Good
group
handling
harmonization
hematologic
histocompatibility complex
Hospitalization
Hospitalized
hospitalized patient
Hydroxychloroquine
Hypothesis
ICU
IL-6 levels
Imatinib
immunomodulatory
immunomodulatory drugs
IND
information
Informed consent
inhibitory activity
intensive care
intensive care unit
intention to treat
interfere
International Conference
invasive
Invasive mechanical ventilation
investigational agent
investigator
ITT
Laboratory
Last
limit
limitation
liver
Local
lysosomal sequestration
magnitude
matching placebo
mechanical ventilation
men and women
MHC
mononuclear cell
Mortality
nasal
nasopharyngeal
Nasopharyngeal swab
neutrophil count
New
new oxygen use
non-invasive ventilation
non-rebreather mask
not blinded
null hypothesis
number
objective
off-label
off-label use
Oropharyngeal
outcome
outcomes
oxygen
Oxygenation
P450
packaged
PaO
participant
Participants
Patient
patients
patients with ARDS
patients with COVID-19
PBMCs
performed
Pharmacist
Pharmacy
phase 3 study
Placebo
placebo-controlled
Pneumonia
positive COVID-19
Practice
primary analysis
primary endpoint
principal
progression
proportion
protocol
Psychiatric
Radiographic
random number generator
randomised controlled trial
randomization
Randomized
Randomized controlled trial
receive
receiving
recruitment
Regulatory
renal dysfunction
renal replacement therapy
replication of SARS-CoV-2
required
requiring supplemental oxygen
Respiratory illness
respiratory tract
risk
RT-PCR
Safety
Sample size
sarilumab
SARS-CoV
SARS-CoV-2
secondary endpoint
Seizure
Serious Adverse Events
service
severe disease
severity
significance level
Site
Society
stability
Standard of care
status
stratified
study drug
study enrollment
study outcomes
Study protocol
subject
submitted
supplemental oxygen
Support
Suspension
symptomatic
Tablet
temperature
Test
the patient
the primary endpoint
time
TKI
TKI-induced attenuation of vascular leak
TKI-induced prevention and treatment lung inflammation
Tocilizumab
transcriptomics
Treatment
treatment allocation
treatment arm
treatments for COVID-19
Trial
two-sided
tyrosine kinase inhibitor
uncontrolled
university
unstable angina
vasopressors
ventilator
ventilator free days
viral ABL-1 signalling
website
with COVID-19
[DOI] 10.1186/s13063-020-04819-9 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04819-9 PMC 바로가기 [Article Type] Letter
Statin use is associated with lower disease severity in COVID-19 infection
Article
[키워드] adjusted
Admission
age
analysed
association
clinical
Clinical outcome
COVID-19 infection
COVID-19 patients
death
disease severity
dyslipidaemia
Endocrine system and metabolic diseases
Gender
hyperlipidemia
ICU
ICU admission
invasive
Logistic
medication
outcome
outcomes
oxygen
Patient
Regression model
requiring supplemental oxygen
retrospective cohort
risk
Risk factors
severity
significant difference
Singapore
statin
statistical significance
statistical test
Support
Treatment
two-sided
was determined
were used
with COVID-19
[DOI] 10.1038/s41598-020-74492-0 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-020-74492-0 PMC 바로가기 [Article Type] Article
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
Article
[키워드] 1:1
95% confidence interval
Anti-inflammatory
Anti-viral
baseline
clinical
clinical trials
cohort study
Colchicine
Community
coronavirus
COVID-19
COVID-19 patient
Cytokine storm
death
defined
discharged
Endpoint
FIVE
Follow-up
group
hospital
immunomodulatory
improvement
In-hospital death
Mortality
observation
Odds ratio
Patient
PCR positive
performed
primary endpoint
proportion
receiving
requiring supplemental oxygen
scale
secondary
single-center
Standard of care
storm
stratified
suggested
Treatment
Viral pneumonia
weather
with COVID-19
[DOI] 10.3390/jcm9092961 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/jcm9092961 PMC 바로가기 [Article Type] Article
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 24 hour
7-point ordinal scale
absence
addition
administration
Admission
ALT
anticipated
assigned
AST
baseline
biological parameters
candidate
Care
clinical
Clinical research
clinical status
clinical trial
clinician
Comorbidity
conditions
Control
control arm
control group
Coronavirus infections
Council
COVID 19
COVID-19
COVID-19 infection
criteria
current
D-dimer
Day
death rate
decrease
discharge
dissemination
dose
drug
Duration
early stage
Efficacy
element
ELISA
enrolment
EudraCT
European
evaluate
exclusion criteria
exploratory
extracorporeal membrane oxygenation
Frame
harmonization
hospitalisation
hospitalised
hospitalised patient
hyperinflammatory status
hypersensitivity
Hypothesis
identify
IL-6
IL-6 levels
IL-6 receptor inhibitors
IL-6R
In-hospital
incidence
Inclusion
inclusion criteria
independent
Infection
Informed
inhibitor
interstitial pneumonia
Intervention
intervention group
intestinal perforation
Invasive mechanical ventilation
investigator
investigator-initiated
lactation
Local
marker
measure
mechanical ventilation
moderate
moderate-severe
neutrophil count
Non-invasive
non-invasive ventilation
number
number of death
objective
Open label trial
outbreak
outcome
oxygen
Oxygenation
pandemic
participant
pathogen
patients treated
performed
Platelet
Pneumonia
positive
positive RT-PCR
Positive test
Prednisone
Presence
Prevent
progression
protocol
random
randomisation
randomised
randomised controlled trial
receive
recruited
recruitment
Registered
reported
requiring supplemental oxygen
responsible
routine clinical practice
RT-PCR
SAEs
Sample size
sarilumab
SARS-CoV-2
SARS-COV-2 infection
score
Sepsis
Serious Adverse Event
serum
Severe COVID-19 Infection
single center
single dose
Spain
Standard
Standard of care
status
Study protocol
Subcutaneous
subcutaneous injection
the patient
therapy
treated
Treatment
treatment arm
treatment with tocilizumab
Trial
ULN
union
unit
verbal
website
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter
Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease
Research Article
[키워드] Abnormalities
abnormality
appear
Arrhythmias
assessment
baseline
Blood
caused
changes in
Clinical data
Clinical outcome
coronavirus 2019 disease
coronavirus disease
Course
COVID-19
diarrhea
died
dose
evaluate
failure
grade 3
HCQ
HCQ therapy
highlighting
Hospitalization
hospitalized patient
hospitals
Hydroxychloroquine
hypoxia
IMPROVE
in vitro activity
in-hospital mortality
incident
liver
mechanical ventilation
New York City
occurred
outcomes
Patient
proportion
QT prolongation
randomized trials
receiving
requiring supplemental oxygen
Respiratory Coronavirus
Result
retrospective cohort study
Safe
Safety
SARS-CoV-2
supplemental oxygen
sustained
therapy
Tolerability
tolerable
Treatment
ventricular
vomiting
with COVID-19
worldwide pandemic
[DOI] 10.1371/journal.pone.0236778 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0236778 PMC 바로가기 [Article Type] Research Article
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial
Letter
[키워드] activity
adverse event
allergic reaction
anti-SARS-CoV-2
anti-SARS-CoV-2 antibody
Anti-SARS-CoV-2 plasma
Anti-viral
blinded
Blood
blood product
center
Chest radiography
Clinical improvement
Clinical outcome
clinical status
clinical trial
clinician
collected
Columbia University
control arm
convalescent plasma
coronavirus
COVID-19
COVID-19 symptom
criteria
cumulative
Date
defined
Dilution
discharge
dissemination
Donor
ECMO
Efficacy
Efficacy and safety
element
evaluate
Evaluating
Evidence
extracorporeal membrane oxygenation
hazard
hazard ratio
HBV
HCV
HIV
hospital
Hospitalized
hospitalized patient
IgA deficiency
immune
incidence
include
Infection
Influenza
Invasive mechanical ventilation
mechanical ventilation
multi-organ failure
nasopharyngeal
Nasopharyngeal swab
New York
Non-invasive
number
objective
occur
oropharyngeal swab
outcome
oxygen saturation
participant
Participants
patients hospitalized
PCR test
PCR-negative
per-protocol analysis
peripheral capillary
plasma
platform
post-hoc analysis
Pregnancy
primary endpoint
protocol
randomization
Randomized
Randomized controlled trial
randomized, controlled trial
randomly permuted block
receive
Registered
Remdesivir
requiring high-flow oxygen
requiring supplemental oxygen
Research
Respiratory failure
retrospective
Ritonavir
safety endpoint
Sample size
SARS-CoV-2
SARS-CoV-2 antibody
SARS-COV-2 infection
screened
Serious Adverse Event
seven-point ordinal scale
severe COVID-19
severe SARS-CoV-2
severely ill adult
single-center
spike trimer
SpO2
status
study participant
study period
Study protocol
supplemental oxygen
tested
therapy
transfused
Treatment
treatment for COVID-19
Trial
undergo
USA
Version
Volunteer
Wald test
website
with COVID-19
World Health Organization
ZIKV
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
7-point ordinal scale
accelerate
activities
activity
acute respiratory syndrome
adaptive
addition
administration
Admission
airway
Akershus
allocation sequence
Analysis
analysis
anticipated
approach
automatically
baseline
Biochemistry
Biomarker
blinded
Blinding
Blood
C-reactive protein
cardiac troponin
Chloroquine
clinical
Clinical outcome
Clinical practice
clinical status
clinical symptom
collected
condition
coronavirus
coronavirus disease
COVID-19
Culture
database
Department
disease
dissemination
early treatment
element
Endpoint
examined
excluded
extracorporeal membrane oxygenation
Good
harmonization
hepatic injury
history
hospital
Hospital admission
hospitalisation
hospitalised
hospitalised patient
Hospitalized
Hydroxychloroquine
Hypothesis
In-hospital
include
independent
Inpatient
intensive care
intensive care unit
International Conference
Intervention
intervention arm
Invasive mechanical ventilation
Laboratory
marker
Microbiology
Mortality
nasopharyngeal
NEWS2
non-invasive ventilation
Norway
number
Nurse
objective
open label
Oropharyngeal
Oropharyngeal sampling
outcome
oxygen
participant
Patient
patients
peptide
Placebo
polymerase chain
polymerase chain reaction
positive
Practice
Pragmatic
pragmatic trial
primary endpoint
profile
Prolonged
Protein
protocol
QT interval
randomisation
randomised
randomised controlled
randomised controlled trial
randomization
Randomized
Randomized controlled trial
recruited
recruitment
Registered
renal
requiring supplemental oxygen
resource
responsible
RT-PCR
Safe
Sample size
SARS-CoV-2
SARS-CoV-2 viral load
score
secondary
Seven
standard care
statistical analyses
status
Study protocol
subjects
Surveillance
therapy
transcriptase
Treatment
treatment allocation
Trial
Two-arm
university
use of hydroxychloroquine
Viral load
virological clearance
viruses
vital signs
website
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter
Psychological intervention on COVID-19 A protocol for systematic review and meta-analysis
4900
[키워드] 95% confidence interval
Admission
adverse events
calculated
change
Chinese
CIs
clinical
clinical heterogeneity
Cochrane Library
cough
COVID-19
database
Dyspnea
effective
Effectiveness
Effects
Efficiency
Evidence
expressed
GAD-7
Hamilton Anxiety Scale
independent
Infrastructure
Intervention
journal
literature
mean difference
Meta-analysis
Mild
Non-invasive
Novel coronavirus infection
outcomes
Patient
PHQ-9
physical
positive
Primary outcomes
protocol
psychological condition
Psychological intervention
random effect model
randomised controlled trial
registry
reported
requiring supplemental oxygen
researcher
risk
RT-PCR
scale
searched
Secondary outcomes
SMD
standardized mean difference
suggested
systematic review
time
Treatment
upper respiratory tract
used to evaluate
Web of Science
WHO
[DOI] 10.1097/MD.0000000000020335 PMC 바로가기 [Article Type] 4900
[DOI] 10.1097/MD.0000000000020335 PMC 바로가기 [Article Type] 4900
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Research
[키워드] acute respiratory syndrome
antiretroviral
Blood
case sery
China
clinical
clinical feature
Clinical features
Clinical outcome
collected
Confirmed
coronavirus
coronavirus disease
Course
COVID-19
deaths
detectable
diagnosed
diarrhea
exposure
Features
Fever
Final
finding
Follow-up
hospital
hospitalized patient
human-to-human transmission
Importance
individual
Infection
initial
intensive care
Laboratory
Liver function
Lopinavir-ritonavir
management
measure
median age
mild respiratory
Nasopharyngeal swab
nasopharynx
nausea
objective
outbreak
outcome
oxygen
participant
Patient
patients
patients treated
PCR
PCR cycle
PCR-confirmed
Point
polymerase chain
progressive respiratory failure
prolonged viral shedding
radiologic
Relevance
required
requiring supplemental oxygen
resolved
respiratory tract infection
Result
SARS-CoV-2
SARS-COV-2 infection
setting
Singapore
Spread
Stool
supplemental oxygen
sustained
threshold value
treated
Treatment
upper respiratory tract
Urine
viral shedding
vomiting
was reduced
women
Wuhan, China
[DOI] 10.1001/jama.2020.3204 PMC 바로가기 [Article Type] Research
[DOI] 10.1001/jama.2020.3204 PMC 바로가기 [Article Type] Research